Myoinositol supplementation for the prevention of gestational diabetes in at-risk patients. Systematic review and meta-analysis.
Diabetes prevention
Gestational diabetes mellitus
Incidence
Inositol
Meta-analysis
Journal
Current research in pharmacology and drug discovery
ISSN: 2590-2571
Titre abrégé: Curr Res Pharmacol Drug Discov
Pays: Netherlands
ID NLM: 9918300982506676
Informations de publication
Date de publication:
2023
2023
Historique:
received:
23
09
2022
revised:
07
11
2022
accepted:
17
11
2022
entrez:
27
12
2022
pubmed:
28
12
2022
medline:
28
12
2022
Statut:
epublish
Résumé
Gestational diabetes (GD) is associated with an increase in maternal and fetal morbidity. The risk factors involved have been clearly identified but no prevention strategies have yet provided robust evidence of their efficacy. Myoinositol has insulin sensitization properties and is of potential interest in the treatment of the disorder. The aim of this work was to assess the efficacy of myoinositol supplementation during pregnancy to prevent GD in patients with known risk factors. A systematic literature review was performed on studies comparing the effects of myoinositol supplementation and placebo on the occurrence of GD in at-risk pregnant women. The main judgement criterion was diagnosis of GD between 24 and 28 gestational weeks by an oral glucose tolerance test. The secondary judgement criteria were the occurrence of maternal fetal complications and the need to initiate insulin treatment to manage GD. Nine studies were included in the meta-analysis. The results showed a significantly higher risk of GD in patients on placebo than in those receiving myoinositol (RR = 2.58, CI 95%: 1.68 to 3.97, p < 0.0001) but wide variations between studies (I Myoinositol supplementation taken from the beginning of pregnancy reduces the incidence of GD and could be of interest at a dose of 4 g/day as a prevention strategy for patients with identified risk factors.
Sections du résumé
Background
UNASSIGNED
Gestational diabetes (GD) is associated with an increase in maternal and fetal morbidity. The risk factors involved have been clearly identified but no prevention strategies have yet provided robust evidence of their efficacy. Myoinositol has insulin sensitization properties and is of potential interest in the treatment of the disorder.
Aim
UNASSIGNED
The aim of this work was to assess the efficacy of myoinositol supplementation during pregnancy to prevent GD in patients with known risk factors.
Method
UNASSIGNED
A systematic literature review was performed on studies comparing the effects of myoinositol supplementation and placebo on the occurrence of GD in at-risk pregnant women. The main judgement criterion was diagnosis of GD between 24 and 28 gestational weeks by an oral glucose tolerance test. The secondary judgement criteria were the occurrence of maternal fetal complications and the need to initiate insulin treatment to manage GD.
Results
UNASSIGNED
Nine studies were included in the meta-analysis. The results showed a significantly higher risk of GD in patients on placebo than in those receiving myoinositol (RR = 2.58, CI 95%: 1.68 to 3.97, p < 0.0001) but wide variations between studies (I
Conclusion
UNASSIGNED
Myoinositol supplementation taken from the beginning of pregnancy reduces the incidence of GD and could be of interest at a dose of 4 g/day as a prevention strategy for patients with identified risk factors.
Identifiants
pubmed: 36573918
doi: 10.1016/j.crphar.2022.100140
pii: S2590-2571(22)00060-8
pmc: PMC9772804
doi:
Types de publication
Journal Article
Review
Retracted Publication
Langues
eng
Pagination
100140Investigateurs
Amélie Delabaere
(A)
Anthéa Bertrand
(A)
Denis Gallot
(D)
Igor Tauveron
(I)
Marion Rouzaire
(M)
Bruno Pereira
(B)
Commentaires et corrections
Type : RetractionIn
Informations de copyright
© 2022 Published by Elsevier B.V.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Contemp Clin Trials. 2015 Nov;45(Pt A):139-45
pubmed: 26343745
Int J Endocrinol. 2016;2016:9132052
pubmed: 27807448
J Matern Fetal Neonatal Med. 2013 Jul;26(10):967-72
pubmed: 23327487
Obstet Gynecol. 2015 Aug;126(2):310-315
pubmed: 26241420
Int J Mol Sci. 2019 Nov 18;20(22):
pubmed: 31752081
J Matern Fetal Neonatal Med. 2019 Jul;32(13):2249-2255
pubmed: 29343138
Diabet Med. 2011 Aug;28(8):972-5
pubmed: 21414183
J Matern Fetal Neonatal Med. 2016 Oct;29(19):3234-7
pubmed: 26698911
Endocr J. 2014;61(2):111-7
pubmed: 24189751
BJOG. 2018 Feb;125(3):299-308
pubmed: 28544572
Biochimie. 2013 Oct;95(10):1811-27
pubmed: 23764390
Hum Reprod. 2008 Jun;23(6):1439-46
pubmed: 18375940
Diabetes Care. 2017 Jun;40(6):759-763
pubmed: 28325784
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Diabetes Care. 2013 Apr;36(4):854-7
pubmed: 23340885
Acta Diabetol. 2018 Aug;55(8):805-812
pubmed: 29774465
Int J Food Sci Nutr. 2021 Aug;72(5):670-679
pubmed: 33238798
Biomed Rep. 2017 Aug;7(2):169-172
pubmed: 28804631
Eur Rev Med Pharmacol Sci. 2011 Aug;15(8):931-6
pubmed: 21845803
Clin Ter. 2017 Jul-Aug;168(4):e240-e247
pubmed: 28703838
J Matern Fetal Neonatal Med. 2020 Mar;33(5):743-751
pubmed: 30558466
Cochrane Database Syst Rev. 2020 Jun 11;6:CD012394
pubmed: 32526091
Gynecol Endocrinol. 2012 Jun;28(6):440-2
pubmed: 22122627
Int J Exp Diabetes Res. 2002;3(1):47-60
pubmed: 11900279
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Int J Surg. 2010;8(5):336-41
pubmed: 20171303